Bayer-Monsanto Merger "Anti-competitive," Bad For Monsanto InvestorsMark Melin
The Bayer-Monsanto merger reveals truths about Monsanto and its product cycle that have led CLSA to downgrading the stock to “underperform” from buy. In a September 15 report, analyst Mark Connelly says the details of the proposed deal point to structural weakness inside Monsanto and their product cycle that should be of concern to investors – concerns that are not properly priced into the market. Yesterday former US Department of Justice officials expressed concern over the merger.
Worries over merger are justified on several . . .
This content is exclusively for paying members. Access all of our content on including years of timeless investment news and in depth analysis for only a few dollars a month by signing up below and support quality content and journalism, or learn more about our premium content here
If you are subscribed and having an account error please clear cache and then cookies if that does not work email firstname.lastname@example.org and we will get back to you as quick as humanly possible - we love (all our but in particular our) paying readers